SCHEMBL1775868

SCHEMBL1775868

CC(C)(F)c1cc(OCc2ccccc2)cc2nc(N)c3nc4n(c3c12)CCOC4

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.36
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
GRM2 Q14416 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
TLR7 Q9NYK1 4/20 0.33
GAA P10253 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
MGMT P16455 1/20 0.32
KMT2A Q03164 1/20 0.32
IGF1R P08069 2/20 0.32
RAF1 P04049 2/20 0.32
BRAF P15056 2/20 0.32
PRMT5 O14744 1/20 0.31
PRKDC P78527 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311081 0.81 PRKDC (0.43) GRM5TP53MAPTNPC1RAB9A
SCHEMBL2243546 0.79 DHFR (0.33) HRH4TLR7ALDH1A1
SCHEMBL1776124 0.73 GRM5 (0.36) GRM5TP53MAPTNPC1RAB9A
SCHEMBL1775006 0.71 MAPT (0.36) GRM5TP53MAPTNPC1RAB9A
SCHEMBL1775116 0.70 TLR7 (0.36) GRM5TLR7ALDH1A1KDM4EHPGD
SCHEMBL8114384 0.69 KDM4E (0.46) MAPTTLR7GAAALDH1A1KDM4E
SCHEMBL311936 0.68 PRKDC (0.45) GRM5TP53MAPTNPC1RAB9A
SCHEMBL2244245 0.68 DCPS (0.34) GRM5TLR7KDM4E
SCHEMBL4702114 0.68 ACHE (0.38) TP53MAPTHRH4TLR7ALDH1A1
SCHEMBL4704199 0.67 KCNA5 (0.36) TP53MAPTNPC1RAB9AHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207162-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-06-26 US disclosed
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2011-08-25 US disclosed
US-7943609-B2 Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides 3M INNOVATIVE PROPRERTIES COMPANY (US) 2011-05-17 US disclosed
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds IFNAR1, IFNG, IL4 GRM5 2061/4885TP53 339/4885MAPT 4638/4885
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 GRM5 2061/4885TP53 339/4885MAPT 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.